Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/18/21 (What's New)

Summary

  • Switching patients from stable PI-based, NNRTI-based, or elvitegravir/cobicistat-based regimens to doravirine/lamivudine/tenofovir DF found to be noninferior at Week 48 primary endpoint analysis to continuing baseline ART in the DRIVE-SHIFT trial[Johnson 2019]
    • In patients receiving baseline PI-based ART, switch to doravirine/lamivudine/tenofovir DF significantly reduced low density lipoprotein cholesterol and non–high density lipoprotein cholesterol vs continuing PI/ritonavir-based ART
    • At Week 144, (end of the extension phase), 80.1% of those in the immediate switch group and 83.7% of those in the delayed switch group maintained HIV-1 RNA < 50 copies/mL by FDA snapshot analysis[Kumar 2021]

Action required